Logo image of AMLX

AMYLYX PHARMACEUTICALS INC (AMLX) Stock Overview

NASDAQ:AMLX - US03237H1014 - Common Stock

9.16 USD
+0.66 (+7.76%)
Last: 8/26/2025, 8:14:50 PM
9 USD
-0.16 (-1.75%)
Pre-Market: 8/27/2025, 8:04:41 AM

AMLX Key Statistics, Chart & Performance

Key Statistics
52 Week High9.38
52 Week Low2.08
Market Cap816.80M
Shares89.17M
Float72.49M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.5
PEN/A
Fwd PEN/A
Earnings (Next)11-05 2025-11-05/bmo
IPO01-07 2022-01-07
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


AMLX short term performance overview.The bars show the price performance of AMLX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 50 100 150

AMLX long term performance overview.The bars show the price performance of AMLX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 100 200 300

The current stock price of AMLX is 9.16 USD. In the past month the price increased by 15.22%. In the past year, price increased by 312.61%.

AMYLYX PHARMACEUTICALS INC / AMLX Daily stock chart

AMLX Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 45.57 696.62B
JNJ JOHNSON & JOHNSON 17.65 425.05B
AZN ASTRAZENECA PLC-SPONS ADR 18.03 248.19B
NVO NOVO-NORDISK A/S-SPONS ADR 14.19 245.90B
NVS NOVARTIS AG-SPONSORED ADR 14.31 245.16B
MRK MERCK & CO. INC. 11.04 212.29B
PFE PFIZER INC 7.35 141.68B
SNY SANOFI-ADR 11.38 122.68B
BMY BRISTOL-MYERS SQUIBB CO 7.01 96.09B
GSK GSK PLC-SPON ADR 8.81 80.29B
ZTS ZOETIS INC 24.89 68.60B
TAK TAKEDA PHARMACEUTIC-SP ADR 49.6 46.99B

About AMLX

Company Profile

AMLX logo image Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). The company is headquartered in Cambridge, Massachusetts and currently employs 123 full-time employees. The company went IPO on 2022-01-07. The firm is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.

Company Info

AMYLYX PHARMACEUTICALS INC

43 Thorndike Street

Cambridge MASSACHUSETTS US

Employees: 123

AMLX Company Website

AMLX Investor Relations

Phone: 16176820917

AMYLYX PHARMACEUTICALS INC / AMLX FAQ

What is the stock price of AMYLYX PHARMACEUTICALS INC today?

The current stock price of AMLX is 9.16 USD. The price increased by 7.76% in the last trading session.


What is the ticker symbol for AMYLYX PHARMACEUTICALS INC stock?

The exchange symbol of AMYLYX PHARMACEUTICALS INC is AMLX and it is listed on the Nasdaq exchange.


On which exchange is AMLX stock listed?

AMLX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for AMYLYX PHARMACEUTICALS INC stock?

16 analysts have analysed AMLX and the average price target is 11.86 USD. This implies a price increase of 29.45% is expected in the next year compared to the current price of 9.16. Check the AMYLYX PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is AMYLYX PHARMACEUTICALS INC worth?

AMYLYX PHARMACEUTICALS INC (AMLX) has a market capitalization of 816.80M USD. This makes AMLX a Small Cap stock.


How many employees does AMYLYX PHARMACEUTICALS INC have?

AMYLYX PHARMACEUTICALS INC (AMLX) currently has 123 employees.


What are the support and resistance levels for AMYLYX PHARMACEUTICALS INC (AMLX) stock?

AMYLYX PHARMACEUTICALS INC (AMLX) has a support level at 8.17 and a resistance level at 9.31. Check the full technical report for a detailed analysis of AMLX support and resistance levels.


Is AMYLYX PHARMACEUTICALS INC (AMLX) expected to grow?

The Revenue of AMYLYX PHARMACEUTICALS INC (AMLX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the AMLX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy AMYLYX PHARMACEUTICALS INC (AMLX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does AMYLYX PHARMACEUTICALS INC (AMLX) stock pay dividends?

AMLX does not pay a dividend.


When does AMYLYX PHARMACEUTICALS INC (AMLX) report earnings?

AMYLYX PHARMACEUTICALS INC (AMLX) will report earnings on 2025-11-05, before the market open.


What is the Price/Earnings (PE) ratio of AMYLYX PHARMACEUTICALS INC (AMLX)?

AMYLYX PHARMACEUTICALS INC (AMLX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.5).


What is the Short Interest ratio of AMYLYX PHARMACEUTICALS INC (AMLX) stock?

The outstanding short interest for AMYLYX PHARMACEUTICALS INC (AMLX) is 9.93% of its float. Check the ownership tab for more information on the AMLX short interest.


AMLX Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to AMLX. When comparing the yearly performance of all stocks, AMLX is one of the better performing stocks in the market, outperforming 98.73% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

AMLX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to AMLX. No worries on liquidiy or solvency for AMLX as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AMLX Financial Highlights

Over the last trailing twelve months AMLX reported a non-GAAP Earnings per Share(EPS) of -2.5. The EPS decreased by -420.83% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -96.4%
ROE -111.75%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%36.99%
Sales Q2Q%100%
EPS 1Y (TTM)-420.83%
Revenue 1Y (TTM)-99.86%

AMLX Forecast & Estimates

16 analysts have analysed AMLX and the average price target is 11.86 USD. This implies a price increase of 29.45% is expected in the next year compared to the current price of 9.16.

For the next year, analysts expect an EPS growth of 23.73% and a revenue growth -100% for AMLX


Analysts
Analysts86.25
Price Target11.86 (29.48%)
EPS Next Y23.73%
Revenue Next Year-100%

AMLX Ownership

Ownership
Inst Owners75.81%
Ins Owners9.33%
Short Float %9.93%
Short Ratio4.64